Brii Biosciences Launches Dual-Targeting siRNA Drug Discovery Platform

• Brii Biosciences launched BRiSC today, a proprietary discovery platform for next-generation, dual-targeting small interfering RNA therapies.
• The platform is designed to enable a single treatment to silence two distinct targets, initially focusing on prevalent metabolic dysfunctions.
• Four complementary technologies aim to improve siRNA selectivity, performance and therapeutic reach.
• Multiple internal discovery programs are already progressing through the platform, supported by expanded research and preclinical development capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150730PR_NEWS_USPR_____CN73090) on October 15, 2026, and is solely responsible for the information contained therein.